HC Wainwright Brokers Decrease Earnings Estimates for ThermoGenesis Holdings, Inc. (NASDAQ:THMO)

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) – Research analysts at HC Wainwright cut their Q3 2024 EPS estimates for ThermoGenesis in a note issued to investors on Tuesday, November 14th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings per share of $0.02 for the quarter, down from their previous forecast of $0.03. HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for ThermoGenesis’ current full-year earnings is ($3.26) per share. HC Wainwright also issued estimates for ThermoGenesis’ FY2024 earnings at $0.08 EPS.

ThermoGenesis Price Performance

Shares of ThermoGenesis stock opened at $0.99 on Wednesday. The firm has a fifty day moving average price of $1.14 and a 200 day moving average price of $1.31. ThermoGenesis has a 1 year low of $0.90 and a 1 year high of $6.75.

Institutional Investors Weigh In On ThermoGenesis

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of ThermoGenesis during the 1st quarter worth approximately $35,000. Jane Street Group LLC purchased a new position in ThermoGenesis during the first quarter worth approximately $37,000. Two Sigma Securities LLC purchased a new position in ThermoGenesis during the first quarter worth approximately $37,000. Renaissance Technologies LLC boosted its position in ThermoGenesis by 306.3% during the third quarter. Renaissance Technologies LLC now owns 156,000 shares of the company’s stock worth $39,000 after purchasing an additional 117,600 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in ThermoGenesis during the first quarter worth approximately $40,000. Institutional investors and hedge funds own 4.71% of the company’s stock.

ThermoGenesis Company Profile

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.